United States Drug Delivery Devices Market Outlook to 2023-Central Venous Catheters, Infusion Systems, Needle Free Injections and Metered Dose Inhaler Devices

Table of Contents

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 4

1.2 List of Figures 8

2 Introduction 9

2.1 What Is This Report About? 9

2.2 Drug Delivery Devices Market Segmentation 9

2.3 Definitions of Markets Covered in the Report 10

3 Drug Delivery Devices Market, United States 13

3.1 Drug Delivery Devices Market, United States, Revenue ($m), 2009-2023 13

3.2 Drug Delivery Devices Market, United States, Revenue Mix ($m), 2016 15

3.3 Drug Delivery Devices Market, United States, Category Contribution by Revenue ($m), 2016 16

3.4 Drug Delivery Devices Market, United States, Category Comparison by Revenue ($m), 2009-2023 17

3.5 Drug Delivery Devices Market, United States, Revenue ($m), 2009-2016 19

3.6 Drug Delivery Devices Market, United States, Revenue ($m), 2016-2023 21

3.7 Drug Delivery Devices Market, United States, Volume (Units), 2009-2023 23

3.8 Drug Delivery Devices Market, United States, Volume (Units), 2009-2016 25

3.9 Drug Delivery Devices Market, United States, Volume (Units), 2016-2023 27

3.10 Drug Delivery Devices Market, United States, Company Share by Revenue ($m), 2016 29

4 Central Venous Catheters Market, United States 31

4.1 Central Venous Catheters Market, United States, Revenue Mix ($m), 2016 31

4.2 Central Venous Catheters Market, United States, Segment Contribution (%), 2016 32

4.3 Central Venous Catheters Market, United States, Revenue ($m), 2009-2016 33

4.4 Central Venous Catheters Market, United States, Revenue ($m), 2016-2023 35

4.5 Central Venous Catheters Market, United States, Volume (Units), 2009-2016 37

4.6 Central Venous Catheters Market, United States, Volume (Units), 2016-2023 39

4.7 Central Venous Catheters Market, United States, Distribution Share by Revenue ($m), 2015-2016 41

4.8 Central Venous Catheters Market, United States, Company Share by Revenue ($m), 2016 42

5 Infusion Systems Market, United States 44

5.1 Infusion Systems Market, United States, Revenue Mix ($m), 2016 44

5.2 Infusion Systems Market, United States, Segment Contribution (%), 2016 45

5.3 Infusion Systems Market, United States, Revenue ($m), 2009-2016 46

5.4 Infusion Systems Market, United States, Revenue ($m), 2016-2023 48

5.5 Infusion Systems Market, United States, Volume (Units), 2009-2016 58

5.6 Infusion Systems Market, United States, Volume (Units), 2016-2023 60

5.7 Infusion Systems Market, United States, Distribution Share by Revenue ($m), 2015-2016 70

5.8 Infusion Systems Market, United States, Company Share by Revenue ($m), 2016 71

6 Needle Free Injections Market, United States 73

6.1 Needle Free Injections Market, United States, Revenue ($m), 2009-2016 73

6.2 Needle Free Injections Market, United States, Revenue ($m), 2016-2023 74

6.3 Needle Free Injections Market, United States, Volume (Units), 2009-2016 75

6.4 Needle Free Injections Market, United States, Volume (Units), 2016-2023 76

6.5 Needle Free Injections Market, United States, Distribution Share by Revenue ($m), 2015-2016 77

6.6 Needle Free Injections Market, United States, Company Share by Revenue ($m), 2016 78

7 Metered Dose Inhaler Devices Market, United States 80

7.1 Metered Dose Inhaler Devices Market, United States, Revenue ($m), 2009-2016 80

7.2 Metered Dose Inhaler Devices Market, United States, Revenue ($m), 2016-2023 81

7.3 Metered Dose Inhaler Devices Market, United States, Volume (Units), 2009-2016 82

7.4 Metered Dose Inhaler Devices Market, United States, Volume (Units), 2016-2023 83

7.5 Metered Dose Inhaler Devices Market, United States, Distribution Share by Revenue ($m), 2015-2016 84

7.6 Metered Dose Inhaler Devices Market, United States, Company Share by Revenue ($m), 2016 85

8 Overview of Key Companies in United States, Drug Delivery Devices Market 87

8.1 GlaxoSmithKline Plc 87

8.2 Teleflex Inc 87

8.3 AstraZeneca Plc 87

8.4 C. R. Bard Inc 88

8.5 Hospira Inc 88

8.6 Becton Dickinson and Co 88

8.7 Edwards Lifesciences Corp 88

8.8 Baxter International Inc 89

8.9 Boehringer Ingelheim GmbH 89

8.10 Medtronic Plc 89

8.11 Smiths Medical 90

8.12 B. Braun Melsungen AG 90

8.13 Pfizer Inc 90

8.14 Fresenius Kabi AG 91

8.15 Merck & Co Inc 91

9 Drug Delivery Devices Market Pipeline Products 92

10 Financial Deals Landscape 98

10.1 Acquisition 98

10.2 Asset Transactions 105

10.3 Debt Offerings 107

10.4 Equity Offerings 147

10.5 Merger 223

10.6 Partnerships 225

10.7 Private Equity 252

10.8 Venture Financing 256

11 Recent Developments 285

11.1 Corporate Communications 285

11.2 Financial Announcements 418

11.3 Government and Public Interest 875

11.4 Legal And Regulatory 881

11.5 Other Significant Developments 896

11.6 Product News 919

11.7 Strategy And Business Planning 942

12 Appendix 954

12.1 Research Methodology 955

12.2 GlobalData Consulting 957

12.3 Contact Us 958

12.4 Disclaimer 958

List of Figure

1.2 List of Figures

Figure 1: Drug Delivery Devices Market, United States, Revenue ($m), USD Constant, 2009-2023 35

Figure 2: Drug Delivery Devices Market, United States, Revenue Mix ($m), 2016 37

Figure 3: Drug Delivery Devices Market, United States, Category Contribution (%), 2016 38

Figure 4: Drug Delivery Devices Market, United States, Category Comparison by Revenue ($m), 2009-2023 39

Figure 5: Drug Delivery Devices Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016 41

Figure 6: Drug Delivery Devices Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023 43

Figure 7: Drug Delivery Devices Market, United States, Volume (Units), 2009-2023 45

Figure 8: Drug Delivery Devices Market, United States, Volume (Units), Historic, 2009-2016 47

Figure 9: Drug Delivery Devices Market, United States, Volume (Units), Forecast, 2016-2023 49

Figure 10: Drug Delivery Devices Market, United States, Company Share (%) 2016 51

Figure 11: Central Venous Catheters Market, United States, Revenue Mix ($m), 2016 53

Figure 12: Central Venous Catheters Market, United States, Segment Contribution (%), 2016 54

Figure 13: Central Venous Catheters Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016 55

Figure 14: Central Venous Catheters Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023 57

Figure 15: Central Venous Catheters Market, United States, Volume (Units), Historic, 2009-2016 59

Figure 16: Central Venous Catheters Market, United States, Volume (Units), Forecast, 2016-2023 61

Figure 17: Central Venous Catheters Market, United States, Company Share (%) 2016 64

Figure 18: Infusion Systems Market, United States, Revenue Mix ($m), 2016 66

Figure 19: Infusion Systems Market, United States, Segment Contribution (%), 2016 67

Figure 20: Infusion Systems Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016 68

Figure 21: Infusion Systems Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023 70

Figure 22: Ambulatory Infusion Pumps Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016 72

Figure 23: Syringe Pumps Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016 74

Figure 24: Ambulatory Infusion Pumps Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023 76

Figure 25: Syringe Pumps Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023 78

Figure 26: Infusion Systems Market, United States, Volume (Units), Historic, 2009-2016 80

Figure 27: Infusion Systems Market, United States, Volume (Units), Forecast, 2016-2023 82

Figure 28: Ambulatory Infusion Pumps Market, United States, Volume (Units), Historic, 2009-2016 84

Figure 29: Syringe Pumps Market, United States, Volume (Units), Historic, 2009-2016 86

Figure 30: Ambulatory Infusion Pumps Market, United States, Volume (Units), Forecast, 2016-2023 88

Figure 31: Syringe Pumps Market, United States, Volume (Units), Forecast, 2016-2023 90

Figure 32: Infusion Systems Market, United States, Company Share (%) 2016 93

Figure 33: Needle Free Injections Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016 95

Figure 34: Needle Free Injections Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023 96

Figure 35: Needle Free Injections Market, United States, Volume (Units), Historic, 2009-2016 97

Figure 36: Needle Free Injections Market, United States, Volume (Units), Forecast, 2016-2023 98

Figure 37: Needle Free Injections Market, United States, Company Share (%) 2016 100

Figure 38: Metered Dose Inhaler Devices Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016 102

Figure 39: Metered Dose Inhaler Devices Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023 103

Figure 40: Metered Dose Inhaler Devices Market, United States, Volume (Units), Historic, 2009-2016 104

Figure 41: Metered Dose Inhaler Devices Market, United States, Volume (Units), Forecast, 2016-2023 105

Figure 42: Metered Dose Inhaler Devices Market, United States, Company Share (%) 2016 107

List of Table

1.1 List of Tables

Table 1: Drug Delivery Devices Market, United States, Revenue ($m), USD Constant, 2009-2023 36

Table 2: Drug Delivery Devices Market, United States, Category Contribution by Revenue ($m), 2016 38

Table 3: Drug Delivery Devices Market, United States, Category Comparison by Revenue ($m), 2009-2023 40

Table 4: Drug Delivery Devices Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016 42

Table 5: Drug Delivery Devices Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023 44

Table 6: Drug Delivery Devices Market, United States, Volume (Units), 2009-2023 46

Table 7: Drug Delivery Devices Market, United States, Volume (Units), Historic, 2009-2016 48

Table 8: Drug Delivery Devices Market, United States, Volume (Units), Forecast, 2016-2023 50

Table 9: Drug Delivery Devices Market, United States, Company Share by Revenue ($m), USD Constant, 2016 52

Table 10: Central Venous Catheters Market, United States, Segment Contribution (%), 2016 54

Table 11: Central Venous Catheters Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016 56

Table 12: Central Venous Catheters Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023 58

Table 13: Central Venous Catheters Market, United States, Volume (Units), Historic, 2009-2016 60

Table 14: Central Venous Catheters Market, United States, Volume (Units), Forecast, 2016-2023 62

Table 15: Central Venous Catheters Market, United States, Distribution Share by Revenue ($m), USD Constant, 2015-2016 63

Table 16: Central Venous Catheters Market, United States, Company Share by Revenue ($m), USD Constant, 2016 65

Table 17: Infusion Systems Market, United States, Segment Contribution (%), 2016 67

Table 18: Infusion Systems Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016 69

Table 19: Infusion Systems Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023 71

Table 20: Ambulatory Infusion Pumps Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016 73

Table 21: Syringe Pumps Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016 75

Table 22: Ambulatory Infusion Pumps Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023 77

Table 23: Syringe Pumps Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023 79

Table 24: Infusion Systems Market, United States, Volume (Units), Historic, 2009-2016 81

Table 25: Infusion Systems Market, United States, Volume (Units), Forecast, 2016-2023 83

Table 26: Ambulatory Infusion Pumps Market, United States, Volume (Units), Historic, 2009-2016 85

Table 27: Syringe Pumps Market, United States, Volume (Units), Historic, 2009-2016 87

Table 28: Ambulatory Infusion Pumps Market, United States, Volume (Units), Forecast, 2016-2023 89

Table 29: Syringe Pumps Market, United States, Volume (Units), Forecast, 2016-2023 91

Table 30: Infusion Systems Market, United States, Distribution Share by Revenue ($m), USD Constant, 2015-2016 92

Table 31: Infusion Systems Market, United States, Company Share by Revenue ($m), USD Constant, 2016 94

Table 32: Needle Free Injections Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016 95

Table 33: Needle Free Injections Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023 96

Table 34: Needle Free Injections Market, United States, Volume (Units), Historic, 2009-2016 97

Table 35: Needle Free Injections Market, United States, Volume (Units), Forecast, 2016-2023 98

Table 36: Needle Free Injections Market, United States, Distribution Share by Revenue ($m), USD Constant, 2015-2016 99

Table 37: Needle Free Injections Market, United States, Company Share by Revenue ($m), USD Constant, 2016 101

Table 38: Metered Dose Inhaler Devices Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016 102

Table 39: Metered Dose Inhaler Devices Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023 103

Table 40: Metered Dose Inhaler Devices Market, United States, Volume (Units), Historic, 2009-2016 104

Table 41: Metered Dose Inhaler Devices Market, United States, Volume (Units), Forecast, 2016-2023 105

Table 42: Metered Dose Inhaler Devices Market, United States, Distribution Share by Revenue ($m), USD Constant, 2015-2016 106

Table 43: Metered Dose Inhaler Devices Market, United States, Company Share by Revenue ($m), USD Constant, 2016 108

Table 44: Drug Delivery Devices Market Pipeline Products 114

Table 45: Peaceful Union Acquires Sharklet Technologies 120

Table 46: Serum Institute of India Acquires Nanotherapeutics for USD78.2 Million 121

Table 47: Becton, Dickinson to Acquire C. R. Bard for USD24 Billion 122

Table 48: Shire May Acquire Radius Health 124

Table 49: PixarBio Terminates Acquisition of InVivo Therapeutics for USD77 Million 125

Table 50: Merck and Allergan May Acquire Biogen 126

Table 51: ICU Medical Acquires Hospira Infusion Systems Business from Pfizer 127

Table 52: PAVmed Raises USD5 Million in Private Placement of Notes and Warrants 129

Table 53: Becton, Dickinson to Raise USD725 Million in Public Offering of 2.133% Notes Due 2019 130

Table 54: Becton, Dickinson to Raise USD1 Billion in Public Offering of 2.404% Notes Due 2020 131

Table 55: Becton, Dickinson to Raise USD1.8 Billion in Public Offering of 2.894% Notes Due 2022 132

Table 56: Becton, Dickinson to Raise USD500 Million in Public Offering of Floating Rate Notes Due 2022 133

Table 57: Becton, Dickinson to Raise USD1.75 Billion in Public Offering of 3.363% Notes Due 2024 134

Table 58: Becton, Dickinson to Raise USD2.4 Billion in Public Offering of 3.7% Notes Due 2027 135

Table 59: Becton, Dickinson to Raise USD1.5 Billion in Public Offering of 4.669% Notes Due 2047 136

Table 60: Becton, Dickinson to Raise USD788 Million in Public Offering of 0.368% Notes Due 2019 137

Table 61: Skinvisible Raises USD0.2 Million in Issue of 10% Convertible Promissory Notes Due 2018 138

Table 62: Pfizer Raises USD1.3 Billion in Public Offering of Notes Due 2019 139

Table 63: Pfizer Raises USD1.06 Billion in Public Offering of Notes Due 2020 141

Table 64: Pfizer Raises USD1.06 Billion in Public Offering of 0.25% Notes Due 2022 143

Table 65: Pfizer Raises USD793.5 Million in Public Offering of 1% Notes Due 2027 145

Table 66: Pfizer Raises USD1.06 Billion in Private Placement of 4.2% Notes Due 2047 147

Table 67: Premier Biomedical Raises Funds in Third Tranche of Private Placement of 10% Notes Due 2016 149

Table 68: Catalent Prices Private Placement of 4.75% Notes Due 2024 for USD404.5 Million 150

Table 69: Becton Dickinson Prices Public Offering of 1% Notes Due 2022 for USD500 Million 151

Table 70: Becton Dickinson Prices Public Offering of 1.9% Notes Due 2026 for USD500 Million 153

Table 71: Pfizer Raises USD1 Billion in Public Offering of 1.7% Notes Due 2019 155

Table 72: Pfizer Raises USD1 Billion in Public Offering of 2.2% Notes Due 2021 157

Table 73: Pfizer Raises USD1.8 Billion in Public Offering of 3% Notes Due 2026 159

Table 74: Pfizer Raises USD1 Billion in Public Offering of 4% Notes Due 2036 161

Table 75: Pfizer Raises USD1.3 Billion in Public Offering of 4.125% Notes Due 2046 163

Table 76: Merck Raises USD544 Million in Public Offering of 1.375% Notes Due 2036 165

Table 77: Merck Raises USD544 Million in Public Offering of 0.5% Notes Due 2024 167

Table 78: KalVista Pharma Plans to Raise up to USD6 Million in Public Offering of Shares 169

Table 79: Clearside Biomedical Plans to Raise up to USD50 Million in Public Offering of Shares 170

Table 80: Delcath Systems to Raise USD2.4 Million in Private Placement of Series B Preferred Shares 171

Table 81: MannKind Plans to Raise Funds through Private Placement of Shares upon Exercise of Warrants 172

Table 82: PhaseRx Plans to Raise up to USD15 Million in Public Offering of Shares and Warrants 173

Table 83: EyeGate Pharma Raises USD10 Million in Public Offering of Shares and Warrants 174

Table 84: Zynerba Pharma Plans to Raise up to USD50 Million in Public Offering 176

Table 85: Savara Raises USD42.9 Million in Public Offering of Shares 177

Table 86: Premier Biomedical to Raise Funds through Public Offering of Shares 179

Table 87: MRI Interventions Raises USD13.3 Million in Private Placement of Units 180

Table 88: Alnylam Pharma Prices Public Offering of Shares for USD359.4 Million 181

Table 89: Corium International Raises USD40.3 Million in Public Offering of Shares 183

Table 90: Halozyme Therapeutics Raises USD143.8 Million in Public Offering of Shares 185

Table 91: Bellerophon Therapeutics to Raise USD30 Million in Private Placement of Shares 187

Table 92: Becton Dickinson Raises USD2.47 Billion in Public Offering of Shares 188

Table 93: Becton Dickinson Raises USD2.47 Billion in Public Offering of Depositary Shares 190

Table 94: Savara to Raise up to USD18 Million in Public Offering of Shares 192

Table 95: BioPharmX Raises USD5 Million in Private Placement of Shares and Warrants 193

Table 96: NanoCarrier Agrees to Invest in Tocagen 194

Table 97: Capnia Files Registration Statement for Secondary Offering of Shares 195

Table 98: Adamis Pharma Raises USD17.3 Million in Public Offering of Shares 196

Table 99: AngioDynamics Prices Public Offering of Shares for USD38 Million 198

Table 100: Tocagen Raises USD97.8 Million in IPO 199

Table 101: Premier Biomedical Raises USD0.3 Million in First Tranche of Private Placement of Shares and Warrants 201

Table 102: Catalyst Biosciences Raises USD20.7 Million in Public Offering of Units 202

Table 103: Alliqua BioMedical Raises USD2.8 Million in Private Placement of Shares 204

Table 104: Evoke Pharma Raises USD8 Million in Public Offering of Shares 205

Table 105: Windtree Therapeutics Raises USD10.5 Million in Private Placement of Units 207

Table 106: pSivida Plans to Raise Upto USD20 Million in Public Offering of Shares 209

Table 107: Galena Biopharma Raises Up to USD15.5 Million in Public Offering of Shares and Warrants 210

Table 108: Valeritas Files Registration Statement for IPO for up to USD50 Million 212

Table 109: PAVmed to Raise USD10.4 Million in Private Placement of Shares upon Exercise of Warrants 214

Table 110: Premier Biomedical Withdraws Public Offering of Shares 215

Table 111: PAVmed Raises Additional Funds in Second and Final Tranche of Private Placement of Units 216

Table 112: Corium International Raises USD20 Million in Public Offering of Shares 217

Table 113: Nu-Med Plus Raises USD0.3 Million in Private Placement of Shares 218

Table 114: Capnia Raises USD2 Million in First Tranche of Private Placement of Shares 219

Table 115: PAVmed Raises USD1.5 Million in First Tranche of Private Placement of Units 220

Table 116: Zynerba Pharma Announces Underwriters Exercise of Over-Allotment of Public Offering of Shares 221

Table 117: Heron Therapeutics Raises USD172.6 Million in Public Offering of Shares 223

Table 118: Braeburn Pharma to Raise USD40 Million in Private Placement of Shares 225

Table 119: Capnia Raises USD10 Million in Private Placement of Shares 226

Table 120: Milestone Scientific Completes Underwriters Partial Exercise of Over-Allotment Option of Public Offering of Shares 227

Table 121: AngioDynamics Prices Public Offering of Shares for USD32 Million 229

Table 122: PAVmed to Raise USD5.3 Million in Private Placement of Shares upon Exercise of Warrants 231

Table 123: ConvaTec Raises USD1.8 Billion in IPO 232

Table 124: Galena Biopharma to Raise Funds in Public Offering of Shares 233

Table 125: BioPharmX Raises USD12.5 Million in Public Offering of Units and Warrants 234

Table 126: Delcath Systems Prices Public Offering Shares and Warrants for USD1.3 Million 236

Table 127: T2 Biosystems Raises USD40 Million in Private Placement of Shares 237

Table 128: Intarcia Therapeutics Raises USD215 Million in First Tranche of Private Placement of Shares 238

Table 129: Catalent to Raise Funds through Public Offering of Shares 239

Table 130: MRI Interventions to Raise USD4.3 Million in Private Placement of Units 240

Table 131: BioMarin Pharma Prices Public Offering of Shares for USD720 Million 241

Table 132: Osprey Medical to Raise USD0.8 Million in Share Purchase Plan of CDIs 242

Table 133: Adamis Pharma to Raise USD11 Million in Private Placement of Units 243

Table 134: Dipexium Pharma Merges with PLx Pharma 245

Table 135: Infuseon Therapeutics Enters into Agreement with Oncosynergy 247

Table 136: Nobilis Therapeutics Enters into Agreement with Submersible Systems 248

Table 137: MannKind and One Drop to Enter into Agreement 249

Table 138: TWi Pharma Enters into Agreement with Intech Biopharm 250

Table 139: United Therapeutics Enters into Licensing Agreement with Respira Therapeutics 251

Table 140: Audax Medical Enters into Licensing Agreement with Northeastern University 252

Table 141: CannaRoyalty Enters into Licensing Agreement with NuTrae 253

Table 142: ViaCyte Enters into Research Agreement with W. L. Gore & Associates 254

Table 143: OncoSec Medical Enters into Agreement with Inhibrx 255

Table 144: Northwell Health Enters into Partnership with United Therapeutics 256

Table 145: PharmaJet Enters into Agreement with Serum Institute of India 257

Table 146: Aequus Pharma to Enter into Licensing Agreement with Transdermal Research Pharm Labs 258

Table 147: Valeant Pharma Enters into Licensing Agreement with EyeGate Pharma 259

Table 148: Hikma Pharma Enters into Licensing Agreement with Orion 261

Table 149: A1 Group Enters into Licensing and Distribution Agreement ?with Novaceutical Sciences 262

Table 150: 3M Drug Delivery Systems Partners with Panacea Pharma 263

Table 151: Neuronex Enters Into Licensing Agreement With SK Biopharmaceuticals For DZNS Technology 264

Table 152: Pfizer Terminates its Licensing Agreement with pSivida 265

Table 153: Iatric Systems Enters into Agreement with Hospira 266

Table 154: Tepha Enters into Agreement with Metabolix 267

Table 155: Bayer Enters into Licensing Agreement with DelSiTech 268

Table 156: ALZYN Enters into Licensing Agreement with Transdermal Delivery Solutions 269

Table 157: Themis Medicare Enters into Agreement with Nevakar 270

Table 158: Qualcomm Partners with Boehringer Ingelheim Pharma 271

Table 159: SkinJect Enters into Licensing Agreement with University of Pittsburgh 272

Table 160: BioCorRx Enters into Licensing Agreement with Therakine 273

Table 161: 3i Group to Invest USD136 Million in Cirtec Medical Systems from Century Park Capital Partners 274

Table 162: AGIC Capital to Acquire Ritedose From Olympus Partners 275

Table 163: 410 Medical Raises USD3.3 Million in Series A Financing 276

Table 164: Mentor Capital Invests USD1 Million in GW Pharma 277

Table 165: Otomagnetics Raises USD0.3 Million in Venture Financing 278

Table 166: Pharmajet Raises USD3 Million in Venture Financing 279

Table 167: 410 Medical Raises Additional USD2.1 Million in Series A Financing 280

Table 168: NexGen Medical Systems Raises USD1.5 Million in Venture Financing 281

Table 169: Xeris Pharma Raises Additional USD30 Million in Series C Financing 282

Table 170: Respira Therapeutics to Raise Funds through Series B Preferred Stock Financing 284

Table 171: Ivenix Raises USD50 Million in First Tranche of Equity Financing 285

Table 172: Ivenix Raises USD10 Million in Venture Financing 286

Table 173: Surefire Medical Raises USD12.8 Million in First Round of Series D Financing 287

Table 174: Unilife Raises USD5 Million in Venture Financing 288

Table 175: iVeena Delivery Systems to Raise USD1 Million in Venture Financing 289

Table 176: NapaJen Pharma to Raise Funds in Equity Financing 290

Table 177: Impel NeuroPharma Raises USD21 Million in First Tranche of Series C Financing 291

Table 178: Tocagen Raises USD2.73 Million in Venture Financing 292

Table 179: Impel NeuroPharma Raises USD22.3 Million in Venture Financing 293

Table 180: Unilife Raises USD10.6 Million in Financing Round 294

Table 181: Propeller Health Raises USD21.5 Million in Series C Financing 295

Table 182: BioQ Pharma Raises USD15 Million in Financing Round 296

Table 183: Enable Injections Raises USD30 Million in Series A Financing 297

Table 184: QuiO Technologies Raises USD1.05 Million in Seed Financing 299

Table 185: Impel NeuroPharma Raises USD0.08 Million in Venture Financing 300

Table 186: Kaio Therapy Raises USD0.2 Million in Venture Financing 301

Table 187: Credence MedSystems Raises USD15 Million in Series A Financing 302

Table 188: Chrono Therapeutics Raises USD47.6 Million in Series B Financing 303

Table 189: Enable Injections Raises USD10 Million in Venture Financing 305

Table 190: Fe3 Medical Raises Additional USD3.5 Million in Series B Financing Round 306